Syncom Formulations (India) Share Price Today (SYNCOMF)
TODAY IN ONE LINE
SYNCOMF fell 1.8% on light volume, lagging Nifty's -0.0% move, supported by recent strong earnings.
With a market cap of ₹1,217.3 Cr., it trades at a P/E of 16.16. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Syncom Formulations (India) flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 68.8% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 34.0% and Profit up 106.0%
- ●High Capital EfficiencyROCE of 18.7% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 20.2%
- ●Reasonable ValuationTrading at a moderate P/E of 17.8x
- ●High Promoter HoldingPromoters hold 50.6% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Syncom Formulations (India) News
What changed recently?
Recent events, corporate actions, and announcements.
Syncom Formulations (India) Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Syncom Formulations (India) Limited, framed against the sector median so the premium or discount is obvious at a glance.
Syncom Formulations (India) Limited trades at a P/E of 16.16× and P/B of 2.97×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Syncom Formulations (India) Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Syncom Formulations (India) Limited — derived from the live tape, not yesterday's close.
Syncom Formulations (India) Limited last traded at ₹12.94 with an intraday range of ₹12.86–₹13.24 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹12.94| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 13.93 | +0.99 | +7.62% |
| R3 | 13.55 | +0.61 | +4.69% |
| R2 | 13.39 | +0.45 | +3.50% |
| R1 | 13.17 | +0.23 | +1.75% |
| PIVOT | 13.01 | 0.07 | 0.57% |
| CURRENT | 12.94 | — | — |
| S1 | 12.79 | -0.15 | -1.18% |
| S2 | 12.63 | -0.31 | -2.37% |
| S3 | 12.41 | -0.53 | -4.12% |
| S4 | 12.03 | -0.91 | -7.06% |
SYNCOMF is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹13.08–₹13.16
Trading Below opening range, showing Bearishness
Syncom Formulations (India) Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Syncom Formulations (India) Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Syncom Formulations (India) Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,217.3 Cr. and reported EPS of ₹0.81.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 465 | 489 ▲ 5.2% |
| Sales Growth YoY %Derived | 76.55% | 5.20% |
| Other Income | 17 | 31 ▲ 79.8% |
| Total Income | 482 | 521 ▲ 7.9% |
| 307 | 284 ▼ 7.5% | |
| Gross ProfitDerived | 158 | 205 ▲ 29.9% |
| Gross Margin %Derived | 33.91% | 41.89% |
| 104 | 127 ▲ 23.1% | |
| EBITDA (Operating Profit)Derived | 54 | 77 ▲ 43.0% |
| OPM %Derived | 11.64% | 15.83% |
| 6 | 8 ▲ 27.4% | |
| Profit Before Tax (PBT) | 66 | 101 ▲ 54.4% |
| 16 | 25 ▲ 53.5% | |
| Effective Tax %Derived | 24.54% | 24.41% |
| Total Profit for Period | 49 | 76 ▲ 54.6% |
| Net Profit (Owner's PAT)Derived | 49 | 76 ▲ 54.6% |
| Net Profit Margin %Derived | 10.63% | 15.63% |
| PAT Growth YoY %Derived | 95.28% | 54.62% |
| Earnings Per Share (EPS ₹) | 0.53 | 0.81 ▲ 52.8% |
| Diluted Shares Outstanding (Cr) | 94 | 94 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 5 | -4 ▼ 178.8% |
| Total Expenses (incl. D&A & Interest) | 417 | 419 ▲ 0.6% |
| Material Cost % of RevenueDerived | 59.79% | 45.17% |
| Employee Cost % of RevenueDerived | 11.22% | 13.71% |
| Other Cost % of RevenueDerived | 11.05% | 12.34% |
| Interest Coverage (x)Derived | 56.58x | 61.38x |
| Period | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 224 | 263 ▲ 17.5% | 465 ▲ 76.6% | 489 ▲ 5.2% | |
| Sales Growth YoY %Derived | — | 17.45% | 76.55% | 5.20% | |
| Other Income | 15 | 14 ▼ 7.4% | 17 ▲ 28.9% | 31 ▲ 79.8% | |
| Total Income | 239 | 277 ▲ 15.9% | 482 ▲ 74.2% | 521 ▲ 7.9% | |
142 | 157 ▲ 10.7% | 307 ▲ 95.9% | 284 ▼ 7.5% | ||
| Gross ProfitDerived | 83 | 107 ▲ 29.0% | 158 ▲ 48.0% | 205 ▲ 29.9% | |
| Gross Margin %Derived | 36.81% | 40.44% | 33.91% | 41.89% | |
63 | 77 ▲ 22.1% | 104 ▲ 34.7% | 127 ▲ 23.1% | ||
| EBITDA (Operating Profit)Derived | 20 | 30 ▲ 51.0% | 54 ▲ 82.6% | 77 ▲ 43.0% | |
| OPM %Derived | 8.75% | 11.26% | 11.64% | 15.83% | |
8 | 9 ▲ 19.4% | 6 ▼ 33.9% | 8 ▲ 27.4% | ||
| Profit Before Tax (PBT) | 27 | 34 ▲ 27.8% | 66 ▲ 93.0% | 101 ▲ 54.4% | |
7 | 9 ▲ 32.9% | 16 ▲ 86.1% | 25 ▲ 53.5% | ||
| Effective Tax %Derived | 24.47% | 25.44% | 24.54% | 24.41% | |
| Total Profit for Period | 20 | 25 ▲ 26.1% | 49 ▲ 95.3% | 76 ▲ 54.6% | |
| Net Profit (Owner's PAT)Derived | 20 | 25 ▲ 26.1% | 49 ▲ 95.3% | 76 ▲ 54.6% | |
| Net Profit Margin %Derived | 8.95% | 9.61% | 10.63% | 15.63% | |
| PAT Growth YoY %Derived | — | 26.13% | 95.28% | 54.62% | |
| Earnings Per Share (EPS ₹) | 0.21 | 0.27 ▲ 28.6% | 0.53 ▲ 96.3% | 0.81 ▲ 52.8% | |
| Diluted Shares Outstanding (Cr) | 94 | 94 ▲ 0.0% | 94 ▲ 0.0% | 94 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 2 | 7 ▲ 247.0% | 5 ▼ 32.8% | -4 ▼ 178.8% | |
| Total Expenses (incl. D&A & Interest) | 212 | 243 ▲ 14.5% | 417 ▲ 71.6% | 419 ▲ 0.6% | |
| Material Cost % of RevenueDerived | 44.35% | 49.94% | 59.79% | 45.17% | |
| Employee Cost % of RevenueDerived | 11.53% | 13.31% | 11.22% | 13.71% | |
| Other Cost % of RevenueDerived | 16.53% | 15.87% | 11.05% | 12.34% | |
| Interest Coverage (x)Derived | 4.82x | 5.57x | 56.58x | 61.38x |
Syncom Formulations (India) segment analysis : revenue and profit mix.
Disclosed business segments at Syncom Formulations (India) with their share of revenue and profit, switchable between consolidated and standalone reporting.
Syncom Formulations (India) discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Syncom Formulations (India) Limited.
Our AI distills the core fundamental drivers supporting Syncom Formulations (India) Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Syncom Formulations (India) Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 42.3% YoY, demonstrating strong earnings momentum.
TTM EPS grew 68.8% YoY, reflecting robust operational performance and profitability.
Operating margin 14.49% with net margin 15.63% shows consistent profitability.
ROE 20.19% and ROCE 18.70% indicate efficient capital deployment and returns.
Debt-to-equity ratio 0.0036x with minimal leverage ensures exceptional financial stability.
Key Risks.
TTM revenue declined 9.0% YoY, signaling recent top-line growth deceleration.
Zero dividend yield offers no income to shareholders despite profitability.
Institutional holdings at 0.14% reveal minimal institutional investor confidence.
Stock trades 24% below 52-week high of ₹18.70, indicating weak price momentum.
P/E ratio 17.26x appears elevated relative to modest market capitalization.
Flip Conditions.
Valuation risk. a P/E above 21 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
Syncom Formulations (India) Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Syncom Formulations (India) Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Syncom Formulations (India) Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Syncom Formulations (India) Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Syncom Formulations (India) Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Syncom Formulations (India) Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Syncom Formulations (India) Limited stood at 53.1% of traded volume, against a 20-day average of 53.3%.
Syncom Formulations (India) announcements: results, concalls, ratings, M&A.
Filings Syncom Formulations (India) sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Syncom Formulations (India) files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 45 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Disclosure under SEBI Takeover Regulations
KEDARMAL SHANKARLAL BANKDA has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Copy of Newspaper Publication
Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Syncom Formulations (India) dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Syncom Formulations (India) has declared, sequenced by announce and record date.
Syncom Formulations (India) corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Syncom Formulations (India) Limited: business, sector, key facts.
What Syncom Formulations (India) Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Syncom Formulations (India) Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SYNCOMF, BSE: 524470.
Syncom Formulations (India) Limited is a pharmaceutical company primarily focused on the manufacturing, marketing, and sale of pharmaceutical formulations within India. Their operations are structured across three key segments: manufacturing and dealing in pharmaceutical drugs and formulations, trading of commodities, and renting of properties. The core of their business lies in the production and distribution of a wide array of pharmaceutical products.
Their pharmaceutical product portfolio is extensive and covers various therapeutic areas. This includes antibiotics and anti-infectives to combat bacterial infections, anthelmintics for parasitic worm infestations, antimalarial drugs for malaria treatment, and medications targeting cardiac (heart-related) conditions. Beyond these, they offer formulations for dermatological (skin), gastrointestinal, gynecological, ophthalmological (eye), orthopedic, and pediatric applications. This broad range of offerings demonstrates a commitment to providing solutions across a diverse spectrum of healthcare needs.
In addition to their core pharmaceutical offerings, Syncom Formulations also markets and distributes a line of health and wellness products under the Cratus brand. These products, categorized as life care, evolve, and right nutrition products, likely represent an effort to expand their reach beyond prescription medications and cater to a broader consumer base interested in preventative healthcare and supplementary nutrition. This diversification strategy allows them to engage a wider segment of the market.
The company’s operational scope extends beyond pharmaceutical manufacturing and sales. They actively engage in the trading of commodities, suggesting involvement in the procurement of raw materials and potentially other related goods. Further, the renting of properties indicates a supplementary income stream, possibly through the ownership of facilities used in their operations or through independent real estate holdings. This diversification mitigates risk and provides additional revenue streams.
Syncom Formulations distributes its products in various dosage forms, showcasing a commitment to offering flexible and convenient treatment options for patients. These forms include tablets, capsules, ointments, injections, oral liquids, and effervescent formulations, reflecting adaptability to the needs of different medical conditions and patient preferences. The company also exports its products, demonstrating a presence in international markets beyond India’s borders.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about Syncom Formulations (India) Limited (SYNCOMF).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Syncom Formulations (India) Limited (SYNCOMF)?
The current share price of Syncom Formulations (India) Limited (SYNCOMF) is ₹12.94. Today, the stock has declined by ₹0.23 (1.75%), trading in a range of ₹12.86 to ₹13.24. The stock opened at ₹13.11 with a trading volume of 8,66,854 shares.
02Is Syncom Formulations (India) Limited stock a good investment for long-term?
Syncom Formulations (India) Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,217.3 crores, P/E ratio of 16.16, ROE of 20.19%, and ROCE of 18.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Syncom Formulations (India) Limited stock?
The 52-week high price of Syncom Formulations (India) Limited (SYNCOMF) is ₹18.7, while the 52-week low is ₹10.21. Currently trading at ₹12.94, the stock is 32.2% away from its 52-week low and 30.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Syncom Formulations (India) Limited stock at the current price?
Whether to buy Syncom Formulations (India) Limited stock at ₹12.94 depends on multiple factors. The stock is currently trading with a P/E ratio of 16.16 and P/B ratio of 2.97. Today's performance shows a loss of 1.75%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Syncom Formulations (India) Limited and when is the next dividend?
Syncom Formulations (India) Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹12.94, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Syncom Formulations (India) Limited?
Syncom Formulations (India) Limited's key financial metrics include: P/E Ratio: 16.16, P/B Ratio: 2.97, ROE: 20.19%, ROCE: 18.70%, Dividend Yield: 0.00%, EPS: ₹0.81, Book Value: ₹4.1, and Debt-to-Equity: 0.36. The company's market cap stands at ₹1,217.3 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Syncom Formulations (India) Limited stock performing today in the market?
Syncom Formulations (India) Limited stock opened at ₹13.11 and is currently trading at ₹12.94, showing a decline of ₹0.23 (1.75%). The intraday high is ₹13.24 and low is ₹12.86. The trading volume stands at 8,66,854 shares, indicating moderate market participation today.
08What is the P/E ratio of Syncom Formulations (India) Limited and what does it indicate?
Syncom Formulations (India) Limited has a Price-to-Earnings (P/E) ratio of 16.16, which means investors are willing to pay ₹16.16 for every ₹1 of earnings. With an EPS of ₹0.81, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Syncom Formulations (India) Limited (SYNCOMF) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.